Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821

Journal of Investigative Medicine

Volumn 62, Issue 3, 2014, Pages 638-643

  Mansur, Ashham ^a   Hinz, José ^a   Hillebrecht, Bronja ^a   Bergmann, Ingo ^a   Popov, Aron Frederik ^a   Ghadimi, Michael ^a   Bauer, Martin ^a   Beissbarth, Tim ^a   Mihm, Sabine ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

90 day mortality; Anti PD 1 antibody; Intensive care; Negative costimulatory molecule; Programmed cell death 1 protein; Single nucleotide polymorphism (SNP)

Indexed keywords

HYPERTENSIVE FACTOR; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL INFECTION; ADULT; ALLELE; APACHE; ARTICLE; ARTIFICIAL VENTILATION; B CELL LYMPHOMA; BACTEREMIA; BLOOD SAMPLING; BONE INFECTION; CEREBROVASCULAR ACCIDENT; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; HYPERTENSION; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; PATIENT HISTORY OF SURGERY; PROGNOSIS; RENAL REPLACEMENT THERAPY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE INFECTION; SURGICAL INFECTION; SURVIVAL RATE; SURVIVAL TIME; UROGENITAL TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR; SEPSIS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84896764262     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000059     Document Type: Article

References (40)

1. Angus DC. The lingering consequences of sepsis: a hidden public health disaster? JAMA. 2010; 304: 1833-1834.
2. Cohen J. The immunopathogenesis of sepsis. Nature. 2002; 420: 885-891.
3. Hotchkiss RS, Coopersmith CM, McDunn J.E., et al. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009; 15: 496-497.
4. Stearns-Kurosawa D.J., Osuchowski MF, Valentine C, et al. The pathogenesis of sepsis. Annu Rev Pathol. 2011; 6: 19-48.
5. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008; 29: 617-625.
6. Wang TS, Deng JC. Molecular and cellular aspects of sepsis-induced immunosuppression. J Mol Med (Berl). 2008; 86: 495-506.
7. Boomer JS, Shuherk-Shaffer J, Hotchkiss R.S., et al. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care. 2012; 16: R112.
8. Khamsi R. Execution of sepsis trials needs an overhaul, experts say. Nat Med. 2012; 18: 998-999.
9. Brahmamdam P, Inoue S, Unsinger J., et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010; 88: 233-240.
10. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219-242.
11. + T cell activation during HIV infection. Nat Med. 2010; 16: 452-459.
12. Zhang Y, Li J, Lou J., et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011; 15: R70.
13. Huang X, Venet F, Wang Y.L., et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 2009; 106: 6303-6308.
14. Topalian SL, Hodi FS, Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.
15. Prokunina L, Castillejo-Lopez C, Oberg F., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002; 32: 666-669.
16. + T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum. 2010; 62: 1702-1711.
17. Keir ME, Butte MJ, Freeman G.J., et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704.
18. Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12: 492-499.
19. Kroner A, Mehling M, Hemmer B., et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. 2005; 58: 50-57.
20. Hoffmann TW, Halimi JM, Buchler M, et al. Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation. J Med Genet. 2010; 47: 54-58.
21. Vidal-Castineira J.R., Lopez-Vazquez A, Alonso-Arias R, et al. A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. J Hepatol. 2012; 56: 1230-1238.
22. Bone RC, Balk RA, Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest. 2009; 136: e28.
23. Levy MM, Fink MP, Marshall J.C., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31: 1250-1256.
24. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998; 26: 1793-1800.
25. Knaus WA, Draper EA, Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818-829.
26. Mertens J, Ramadori G, Mihm S. Functional relevance of the IRF-1 promoter polymorphism rs2549009 on transcriptional activity in a native genomic environment. Hum Mol Genet. 2010; 19: 4587-4594.
27. Brown KE, Freeman GJ, Wherry E.J., et al. Role of PD-1 in regulating acute infections. Curr Opin Immunol. 2010; 22: 397-401.
28. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011; 350: 17-37.
29. Weber SU, Schewe JC, Lehmann L.E., et al. Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care. 2008; 12: R128.
30. Frank AJ, Sheu CC, Zhao Y, et al. BCL2 genetic variants are associated with acute kidney injury in septic shock. Crit Care Med. 2012; 40: 2116-2123.
31. Alvarez IB, Pasquinelli V, Jurado J.O., et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010; 202: 524-532.
32. Frebel H, Nindl V, Schuepbach R.A., et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J Exp Med. 2012; 209: 2485-2499.
33. Lazar-Molnar E., Chen B, Sweeney K.A., et al. Programmed death-1 (PD-1)Ydeficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA. 2010; 107: 13402-13407.
34. Molloy S. PD1 turns down the heat. Nat Rev Microbiol. 2010; 8: 612.
35. Velu V, Titanji K, Zhu B., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009; 458: 206-210.
36. + T cell levels in humanized mice. J Immunol. 2013; 190: 211-219.
37. Lipson EJ, Sharfman WH, Drake C.G., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013; 19: 462-468.
38. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167-3175.
39. Hua Z, Li D, Xiang G., et al. PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat. 2011; 129: 195-201.
40. Hayashi M, Kouki T, Takasu N., et al. Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients. Eur J Endocrinol. 2008; 158: 817-822.